Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
Canaccord Genuity Reiterates Buy Rating on AngioDynamics (ANGO)
-
AngioDynamics (ANGO) PT Lowered to $12 at Canaccord Genuity
-
AngioDynamics Announces CE Mark Approval in Europe for the Auryon System
-
AngioDynamics to Participate in Upcoming Investor Conferences
-
AngioDynamics (ANGO) PT Lowered to $13 at Canaccord Genuity
-
AngioDynamics to Participate in a Fireside Chat at the Canaccord Genuity Growth Conference
-
AngioDynamics to Present at the Canaccord Genuity Growth Conference
-
AngioDynamics (ANGO) PT Lowered to $34 at Canaccord Genuity
-
AngioDynamics to Present at the Canaccord Genuity Virtual Growth Conference
-
AngioDynamics (ANGO) PT Raised to $24 at Canaccord Genuity
-
AngioDynamics (ANGO) PT Raised to $18 at Canaccord Genuity
-
AngioDynamics to Participate in a Virtual Fireside Chat at the Canaccord Genuity Growth Conference
-
AngioDynamics to Present at the Canaccord Genuity Growth Conference
-
AngioDynamics (ANGO) PT Raised to $17 at Canaccord Genuity
-
AngioDynamics to Present at the 2017 Canaccord Genuity Growth Conference
-
AngioDynamics to Present at the 2016 Canaccord Genuity Medical Technologies and Diagnostics Forum
-
AngioDynamics to Present at the 2016 Canaccord Genuity Growth Conference
-
Canaccord Genuity Downgrades AngioDynamics (ANGO) to Hold
-
AngioDynamics to Present at the 2015 Canaccord Genuity Medical Technology & Diagnostics Forum
-
Canaccord Genuity Cuts Price Target on AngioDynamics (ANGO) Following 1Q16
-
Canaccord Genuity are Buyers of AngioDynamics (ANGO) on Weakness
-
Notable Analyst Rating Changes 06/19: (SBUX) (BRKR) (ANGO) Upgradedl (JNPR) (NVDA) (PPO) Downgraded
-
Canaccord Genuity Upgrades AngioDynamics (ANGO) to Buy
-
Analysts Sees Synergies and Struggles in AngioDynamics' (ANGO) Latest Acquisition
-
Canaccord Genuity Maintains a 'Hold' on AngioDynamics (ANGO); Bumping Estimates After Q4 Results
-
UPDATE: Canaccord Genuity Downgrades AngioDynamics (ANGO) to Hold; Waiting For Navilyst Synergies To Kick In

